Vincenza Conteduca Selected Research

abiraterone

4/2022	Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
10/2021	Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer.
1/2021	Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging.
6/2020	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy.
1/2020	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.
1/2020	Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide.
1/2019	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.
1/2019	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
1/2019	Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
10/2018	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vincenza Conteduca Research Topics

Disease

72	Prostatic Neoplasms (Prostate Cancer) 04/2022 - 04/2013
35	Neoplasms (Cancer) 04/2022 - 09/2013
10	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 01/2016
9	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2015
5	Adenocarcinoma 03/2022 - 10/2018
3	Circulating Neoplastic Cells 01/2022 - 01/2020
3	Disease Progression 07/2021 - 01/2019
3	Ovarian Neoplasms (Ovarian Cancer) 02/2021 - 05/2014
3	Inflammation (Inflammations) 12/2019 - 01/2016
3	Vasculitis (Vasculitides) 01/2014 - 09/2008
2	Ovarian Epithelial Carcinoma 01/2021 - 12/2018
2	Carcinoma (Carcinomatosis) 01/2021 - 11/2019
2	Kidney Neoplasms (Kidney Cancer) 01/2020 - 01/2016
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2015 - 09/2013
2	Chronic Hepatitis C 01/2014 - 01/2012
2	Cryoglobulinemia 07/2010 - 09/2008
1	Venous Thromboembolism 01/2022
1	Thrombosis (Thrombus) 01/2022
1	Vitamin D Deficiency 05/2021
1	Hematologic Neoplasms (Hematological Malignancy) 02/2021
1	COVID-19 10/2020
1	Autoimmune Diseases (Autoimmune Disease) 06/2020
1	Immune System Diseases (Immune Disorders) 06/2020
1	Frailty 01/2020
1	Small Cell Carcinoma 11/2019
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2019
1	Rheumatoid Arthritis 01/2018
1	Testicular Neoplasms (Testicular Cancer) 05/2017

Drug/Important Bio-Agent (IBA)

23	enzalutamideIBA 04/2022 - 12/2014
23	Androgen Receptors (Androgen Receptor)IBA 10/2021 - 11/2015
22	abirateroneIBA 04/2022 - 06/2014
18	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2013
14	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 11/2015
11	Biological ProductsIBA 07/2021 - 09/2008
10	Docetaxel (Taxotere)FDA Link 01/2022 - 06/2014
8	Cell-Free Nucleic AcidsIBA 03/2022 - 01/2016
7	AndrogensIBA 01/2021 - 09/2013
6	Immune Checkpoint InhibitorsIBA 02/2021 - 04/2018
6	PlatinumIBA 02/2021 - 12/2016
5	Hormones (Hormone)IBA 12/2020 - 11/2015
5	Prostate-Specific Antigen (Semenogelase)IBA 12/2020 - 01/2016
4	Abiraterone AcetateIBA 12/2016 - 05/2015
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 11/2019
3	cabazitaxel FDA Link 01/2022 - 07/2015
3	taxaneIBA 01/2021 - 01/2018
3	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 12/2016
3	RNA (Ribonucleic Acid)IBA 01/2020 - 10/2017
3	Sunitinib (Sutent)FDA Link 01/2019 - 01/2016
3	Chromogranin AIBA 10/2018 - 06/2014
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 08/2021 - 01/2021
2	Chimeric Antigen ReceptorsIBA 02/2021 - 01/2020
2	Phenobarbital (Luminal)FDA Link 01/2021 - 10/2016
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2020 - 12/2016
2	Circulating Tumor DNAIBA 01/2020 - 01/2019
2	NivolumabIBA 01/2020 - 09/2016
2	Axitinib (AG 013736)IBA 01/2019 - 01/2016
2	Everolimus FDA Link 04/2018 - 10/2016
2	CytokinesIBA 08/2016 - 01/2016
2	Angiogenesis InhibitorsIBA 01/2016 - 05/2014
2	Antiviral Agents (Antivirals)IBA 01/2014 - 01/2014
1	Epithelial Cell Adhesion MoleculeIBA 01/2022
1	177Lu-PSMA-617IBA 10/2021
1	Lutetium-177IBA 10/2021
1	Antineoplastic Agents (Antineoplastics)IBA 07/2021
1	Nucleosomes (Nucleosome)IBA 07/2021
1	Taxoids (Taxanes)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	abemaciclibIBA 01/2021
1	Radioisotopes (Radionuclides)IBA 01/2021
1	Melphalan (Alkeran)FDA LinkGeneric 01/2021
1	palbociclibIBA 01/2021
1	Alkylating AgentsIBA 01/2021
1	talazoparibIBA 01/2021
1	ribociclibIBA 01/2021
1	RNA Helicases (RNA Helicase)IBA 01/2020
1	hydrogen sulfite (bisulfite)IBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	Androgen Antagonists (Antiandrogens)IBA 01/2019
1	rovalpituzumab tesirineIBA 01/2019
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	NucleotidesIBA 01/2019
1	delta proteinIBA 01/2019
1	Testosterone (Sustanon)FDA Link 01/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	Topotecan (Hycamtin)FDA LinkGeneric 12/2018
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2018
1	Fluorouracil (Carac)FDA LinkGeneric 12/2018
1	Leucovorin (Folinic Acid)FDA Link 12/2018
1	lenvatinibIBA 04/2018
1	fluoromethylcholineIBA 01/2018
1	Vitamin D FDA LinkGeneric 05/2017

Therapy/Procedure

58	Castration 04/2022 - 06/2014
33	Therapeutics 07/2021 - 07/2010
13	Drug Therapy (Chemotherapy) 01/2022 - 05/2014
6	Immunotherapy 02/2021 - 08/2016
1	Orchiectomy (Orchidectomy) 05/2021
1	Combination Drug Therapy (Combination Chemotherapy) 01/2021
1	Radiotherapy 01/2021
1	Aftercare (After-Treatment) 01/2020